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Abstract
Background: Disulfiram (DS), an antialcoholism medicine, demonstrated strong anticancer activity in the laboratory
but did not show promising results in clinical trials. The anticancer activity of DS is copper dependent. The reaction
of DS and copper generates reactive oxygen species (ROS). After oral administration in the clinic, DS is enriched
and quickly metabolised in the liver. The associated change of chemical structure may make the metabolites of DS
lose its copper-chelating ability and disable their anticancer activity. The anticancer chemical structure of DS is still
largely unknown. Elucidation of the relationship between the key chemical structure of DS and its anticancer
activity will enable us to modify DS and speed its translation into cancer therapeutics.
Methods: The cytotoxicity, extracellular ROS activity, apoptotic effect of DS, DDC and their analogues on
cancer cells and cancer stem cells were examined in vitro by MTT assay, western blot, extracellular ROS
assay and sphere-reforming assay.
Results: Intact thiol groups are essential for the in vitro cytotoxicity of DS. S-methylated diethyldithiocarbamate
(S-Me-DDC), one of the major metabolites of DS in liver, completely lost its in vitro anticancer activity. In vitro
cytotoxicity of DS was also abolished when its thiuram structure was destroyed. In contrast, modification of the ethyl
groups in DS had no significant influence on its anticancer activity.
Conclusions: The thiol groups and thiuram structure are indispensable for the anticancer activity of DS. The
liver enrichment and metabolism may be the major obstruction for application of DS in cancer treatment. A
delivery system to protect the thiol groups and development of novel soluble copper-DDC compound may
pave the path for translation of DS into cancer therapeutics.
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Background
Due to the time and cost for new drug development [1],
drug repositioning has become an attractive strategy in re-
cent years for anticancer drug development [2]. Disulfiram
(DS) specifically inhibits aldehyde dehydrogenase (ALDH)
and blocks the further degradation of acetaldehyde cov-
erted from alcohol. The cummulation of acetaldehyde
causes an unpleasent effect which makes DS one of the
first line anti-alcoholism drugs [3] that has been used in
clinic for almost 70 years. In the last three decades, it was
reported that DS has excellent in vitro anticancer activity
in a wide range of cancer cell lines [4–15]. DS inhibits
proteasome/NFκB pathway [5, 16], MDR1 [17], topoisom-
erase, MMP [18], NPL4 [15] and manipulates MAP kinase
pathways [13]. It eradicates cancer stem cells (CSCs) and
significantly reverses chemoresistance in resistant cancer
cell lines [9–11, 13]. Its cytotoxicity in cancer cells is
copper dependent [8, 9, 19]. Although DS shows high
in vitro toxicity in cancer cells, there was almost no
positive clinical data published in cancer patients
(https://clinicaltrials.gov/ct2/results?term=disulfiram+A
ND+cancer&Search=Search). Therefore, elucidating
the discord between the anticancer activity of DS in
laboratory and clinic is of significant clinical import-
ance in cancer treatment.
In serum, DS is rapidly reduced to form two molecules
of diethyldithiocarbamate (DDC). DDC is a very strong
chelator of transition divalent metal ions, mainly cop-
per(II) (Cu) and zinc (Fig. 1a) [4, 8, 9, 20–23]. The data
from our and other groups demonstrate that the in vitro
cytotoxicity of DS is copper-dependent [4, 9]. In
serum-free medium without copper supplement, DS
completely loses its cytotoxicity in cancer cell lines [13].
Cu plays a crucial role in redox reactions. When DDC
contacts Cu, the chelating reaction between them trig-
gers the generation of reactive oxygen species (ROS) [19,
24], which damage DNA, protein and lipids leading to
cancer cell death. ROS are extremely transient species
with very short lifetime due to their high chemical re-
activity and can only penetrate very short distance in tis-
sues [25]. To target cancer cells, the reaction of DS and
Cu must take place inside or adjacent to cancer cells. In
addition to ROS generated from DDC and Cu reaction,
bio(N,N-diethyldithiocarbamato) copper(II) (Cu-DDC),
the end product derived from DDC and Cu reaction, is
also cytotoxic in cancer cells. [19] Our previous work in-
dicates that there are two phases of cytotoxic effect of
DS on cancer cells, the instant damages induced by the
reaction between DS and Cu and the delayed killing
caused by the end product, Cu-DDC [19]. The sulfhydryl
groups in DDC (dashed box in Fig. 1a) are indispensible
for the chelating reaction between DDC and Cu and for-
mation of Cu-DDC complex. After oral administration,
DS is immediately reduced to form DDC in the gastro-
intestinal system and the bloodstream of the portal vein.
DDC is then enriched in the liver and promptly enzy-
matically converted to S-methyl-DDC (S-Me-DDC) and
gluconidated DDC by S-methyl-transferase and glucuro-
nyl transferase, respectively, or completely degraded to
diethylamine and carbonyl disulfide (Fig. 1b). In the liver,
a b
Fig. 1 Biotransformation and reaction of DS with copper in humans. a Biotransformation of DS. DS is promptly reduced to DDC in the bloodstream
by glutathione reductase system of erythrocytes (1). In liver, DDC is methylated by S-methyltransferase to form S-Me-DDC (2), glucuronidated by
glucuronyl transferase to form glucuronidated DDC (3) and non-enzymatic degradation into diethylamine and carbonyl disulfide (4). b Chelation of DS
with copper. The DDC derived from DS chelates Cu(II) to form Cu(DDC)2 and generates ROS. The thiol group (dashed box) is essential for the reaction.
The solid frame highlights thiuram structure
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the S-Me-DDC is oxidized by microsomal oxidative
metabolism to form diethylthiocarbamic acid methyl
ester (Me-DETC) and S-methyl N,N-diethythiolcar-
bamate sulforxide (MeSO-DETC) [26]. The
Me-DETC and MeSO-DETC are the functional units
for inhibition of ALDH in hepatocytes [26, 27]. So,
DS remains the antialcoholism activity after oral ad-
ministration. All of these DS metabolites lose their
functional thiol groups for chelation of Cu. This
might compromise the anticancer efficacy of DS
when orally administered in cancer patients. There-
fore enrichment and metabolism of DS in the liver
becomes the bottleneck for translation of DS into
cancer treatment. To overcome these limitations, we
recently developed nano-encapsulated DS, e.g. lipo-
somal- and PLGA-DS, which are intravenously in-
jectable [11, 14]. The nano-encapsulation protects
the thiol groups in DS and extends its half-life in
the serum from less than 2 min to over 7 h and suc-
cessfully delivers the intact DS to cancer tissues [14].
In combination with oral administration of copper
gluconate, the nano-encapsulated DS demonstrated
significantly stronger anticancer efficacy in mouse
breast, liver, ovarian, lung and brain cancer models
[11, 14, 28–31] (and our unpublished data).
DS is a small molecule with a molecular weight of
296.4 Da consisting of sulfhydryl groups (dashed box
in Fig. 1a), thiuram structure (brackets in Fig. 1a) and
the ethyl groups. It has been suggested that the sulf-
hydryl groups in DDC are essential for the cytotox-
icity of DS in cancer cells [19, 24]. The role of the
thiuram structure and ethyl groups in the cytotoxicity
of DS in cancer cells is still not clear. Elucidation of
the relationship between the chemical structure and
anticancer activity of DS will be helpful for modifica-
tion of DS and development of novel lead compounds
for further drug development.
In this study, we examined the in vitro anticancer ac-
tivity of several DS and DDC related compounds. Our
results indicate that the intact sulfhydryl groups and the
thiuram structure are critical for maintaining the anti-
cancer activity of DS and DDC. In contrast, modification
of the ethyl groups had no significant effect on their an-
ticancer activity.
Methods
Cell line and reagents
The non-small cell lung cancer (NSCLC) A549 (CCL-185)
and H23 (CRL-5800) cell lines were purchased from ATCC
(Middlesex, UK). Copper chloride (CuCl2, Cu), disulfiram
(DS), diethyldithiocarbamate (DDC), S-methyl-N,N-diethyl-
dithiocarbamate (S-Me-DDC), tetramethylthiuram disulfide
(TMDS), 2-hydroxy-dithiobenzoic acid (HDTA),
4-imidazoledithiocarboxylic acid (IDTA), 2,4,6-Trimercap-
totriazine (TMT) and poly-2-hydroxyethyl methacrylate
(poly-HEMA) were purchased from Sigma (Dorset, UK).
Bis(N,N-diethyldithiocarbamate)-copper(II) (Cu-DDC) was
from Santa Cruz (Dallas, TX, USA). Annexin V kit was
from Roche Applied Sciences (Burgess Hill, UK). Fc Oxy-
BURST Assay Reagents was purchased from Invitrogen,
Molecular Probes (Waltham, MA, USA). ALDEFLUOR kit
was from StemCell Tech (Durham, NC, USA). FITC mouse
Anti-Human CD44 from BD Biosciences (Oxford, UK).
Cell culture and cytotoxicity analysis
The A549 and H23 cells were cultured in DMEM
(Lonza, Wokingham, UK) supplemented with 10% FCS,
2 mM L-glutamine, 50 units/ml penicillin, 50 μg/ml
streptomycin. For in vitro cytotoxicity assay, the cells
(5000/well) were cultured in 96-well flat-bottomed mi-
crotiter plates overnight and exposed to different com-
pounds with or without CuCl2 (10 μM) for 72 h, then
subjected to a standard MTT assay [32].
In vitro spheroid culture and cytotoxicity assay
To culture the spheres, cells were cultured in
poly-HEMA coated ultra-low adherence flasks or plates
to prevent cell adhesion. The spheres were cultured, at a
density of 20,000 cells/ml, in stem cell culture medium
[SCM: serum-free DMEM-F12 (Lonza) supplemented
with B27 (Invitrogen, Paisley, UK), 20 ng/ml epidermal
growth factor (EGF, Sigma), 10 ng/ml basic fibroblasts
growth factor (b-FGF, R & D System, Abingdon, UK),
10 μg/ml insulin, 20 μg/ml heparin, 45% D-glucose, 1%
L-glutamine, 1% penicillin, streptomycin, amphotericin
mix (Sigma)]. After 7 days culture, the spheres were
trypsinised. The dispersed cells were exposed to different
drugs at the indicated concentration for 6 h and sub-
jected to ALDH and CD44 analysis. For in vitro sphere
(See figure on previous page.)
Fig. 2 Cytotoxic effect of DS and related compounds on A549 NSCLC cell line. a The chemical structures of DS-related compounds used in this
study. b Viability curves of A549 cells in different treatments. The cytotoxicity of different compounds in monolayer-cultured A549 cells was
examined. All the treatments except Cu-DDC were supplemented with CuCl2 (in a consistent concentration of 10μM). The cells were dosed for
72 h and then subjected to MTT assay. c IC50 (nM) values. d The morphology of the cells subjected to different treatments. The cells were treated
with S-Me-DDC (10 μM), Cu-DDC (5μM), DDC (1μM), TMDS (1μM), DS (1μM) with or without Cu (10 μM) for 6 h and then release in drug-free
medium overnight. The microscopic images were taken at 40× magnification. e and f Annexin V analysis of apoptosis. The cells were exposed to
different compounds at the above concentrations with or without 10 μM of CuCl2 for 6 h and immediately subjected to Annexin V analysis. g
Western blotting detection of the expression of apoptosis related proteins. The cells were subjected the same treatments as D before western
blotting analysis. N = 3, * p < 0.05, ** p < 0.01
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reformation assay, drug-treated cells were resuspended
in drug-free SCM at a density of 1 × 105 cells/ml and
seeded in ultra-low adherence 24-well plates and cul-
tured for further 7 days.
Detection of ALDH positive population
The ALDH positive population was detected by ALDE-
FLUOR kit (StemCell Tech., Durham, NC, USA) follow-
ing the supplier’s instruction. The cells (2.5 × 105) were
exposed to different drugs for 6 h and were analyzed
after incubation in ALDH substrate containing assay
buffer for 30 min at 37 °C. The specificity was deter-
mined by exposure to diethylaminobenzaldehyde
(DEAB, 30μM), a specific ALDH inhibitor.
Flow cytometric analysis of CD44 expression
The adherent or sphere cells were trypsinised and the
cells (2.5 × 105) were incubated with CD44 antibodies
(BD Pharmingen, Oxford, UK) for 30 min at 4 °C. The
cells (20,000 events) were examined within 1 h after
staining on a BD Facscalibur.
Western blotting analysis
The protein expression levels were determined by stain-
ing with primary antibodies and HRP conjugated sec-
ondary (1:5000, Armersham, Buckinghamshire, UK)
antibody. The cleaved PARP, BCL2, BAX (1:1000,
Abcam, Cambridge, UK) and anti-α-tubulin (1:8000,
Sigma) primary antibodies were diluted in 5% fat-free
milk-TBST. The signal was detected using an ECL West-
ern blotting detection kit (GeneFlow, Staffordshire, UK).
Measurement of extracellular ROS activity
The extracellular ROS levels were determined using Fc
OxyBURST® Assay Reagents (ThermoFisher Sci., Paisley,
UK) following the supplier’s instruction. Briefly, Oxy-
BURST Green was diluted in H2O at a final concentra-
tion of 1μg/ml and 100μl was added into each well of a
black 96-well plate. The compounds and CuCl2 (10μl of
each at 10μM concentration) were added into each well.
The H2O and H2O2 (10μl of 1:100 diluted) were used as
negative and positive control, respectively. N-acetyl-L
-cysteine (NAC, 2μl of 100 mM stock solution) was used
as ROS inhibitor to confirm ROS activity. Immediately,
the oxidative product release in the reaction was de-
tected by a continuous fluorescence increase excited at
492 and emission of 520 nm at integration of 1 s. The
rate of fluorescence increase was proportional to the
amount of oxidative species generated.
Assessment of apoptosis by Annexin-V/PI assay
Apoptotic status was determined by FITC-conjugated
Annexin-V/PI assay kit (Roche) using flow cytometry
following the manufacturer’s instructions. Briefly, 2 × 105
cells were seeded in 6 well flat bottom plates for 24 h
and exposed to drugs for 16 h. Dead cells were collected
and the remaining cells were rinsed with PBS and de-
tached using trypsin. Detached cells were resuspended
in 100 μl binding buffer containing FITC-conjugated
Annexin-V (10 mg/mL)/PI (50 mg/ml) and incubated at
RT for 15 min. The cells were diluted in 400 μl of PBS
and analyzed by a FACScan flow cytometry (Becton
Dickinson, Franklin Lakes, NJ USA). Apoptosis and ne-
crosis were evaluated using FL2 (PI) vs FL1 (Annexin V)
plots. The cells stained with Annexin V only were classi-
fied as early apoptosis and the Annexin V and PI
double-stained cells were classified as late apoptosis or
necrosis.
Statistical analysis
SPSS 13.0 Student’s t test and one-way analysis of vari-
ance (ANOVA) followed by Tukey’s Multiple Compari-
son Test were used to calculate the differences. Data
were expressed as mean ± SD. P ≤ 0.05 was considered as
significantly change.
Results
Intact sulfhydryl groups are indispensible for the
cytotoxicity of DS and DDC but the ethyl groups
can be modified
First, cytotoxicity of five analogues of DS and DDC
(Fig. 2a) in A549 cells was compared. We used
S-Me-DDC, in which the thiol group is methylated, to
determine the importance of thiol group in cytotoxicity
of DS and DDC. We also changed the ethyl groups to
methyl groups in DDC to examine the role of the ethyl
groups in the cytotoxicity of DDC. The cytotoxicity of
these modified DS and DDC was compared with DS,
DDC and Cu-DDC. MTT cytotoxicity assay demon-
strated that methylation of the thiol group in DDC abol-
ishes the cytotoxicity of DDC in Cu-containing medium
(Fig. 2b and c). The IC50 of S-Me-DDC plus Cu
(See figure on previous page.)
Fig. 3 The effect of different compounds on CSC population in A549 cell line. a and b Sphere-reformation assay. The A549 cells formed spheres
after cultured in stem cell medium for 7 days. The spheres were exposed to S-Me-DDC (10 μM), Cu-DDC (5 μM), DDC (1 μM), TMDS (1 μM) and
DS (1 μM) in combination with or without CuCl2 (10 μM) for 6 h. The spheres were trypsinized and cultured in drug free SCM at a density of
5000 cells/well in ultralow attached 24-well plates for another 7 days. The sphere numbers in each well were counted. c and d The effect of
different treatments on ALDH activity in sphere cells. The spheres were trypsinized and exposed to different treatments for 6 h before ALDEFLUOR
analysis. e and f The effect of different treatments on CD44 expression in sphere cells. n = 3, ** < 0.01
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(158,191 nM) is 1250 times higher than that of DDC
plus Cu (125 nM) and also significantly higher than
those of other compounds (3 to 3285 nM). In combin-
ation with Cu, the TMDS, in which the ethyl groups in
DS are replaced with methyl groups, remains highly
toxic in A549 cells. The IC50 of TMDS/Cu (112 nM) is
still significantly higher than that of DS/Cu (3 nM)(p <
0.01). In comparison with Cu-DDC and DDC/Cu,
TMDS/Cu, DS/Cu are more toxic in A549 cells. The
similar effect of these compounds was also observed in
another NSCLC cell line, H23 (Additional file 1). The
morphology of cells after different treatments is showed
in Fig. 2d. DDC, DS, TMDS in combination with Cu and
Cu-DDC induce cancer cell apoptosis. The apoptotic ef-
fect was completely blocked when the thiol group is
methylated (Fig. 2e and f). In line with previous reports
[4, 13], the apoptotic effect of DDC, DS and TMDS is
copper-dependent. The apoptotic results were also con-
firmed by western blotting analysis of the expression of
some apoptosis-related proteins, e.g. cleaved PARP,
BCL2 and BAX (Fig. 2g).
The intact thiol groups are essential for targeting CSC-like
cells
Our previous studies indicate that DS very strongly tar-
gets CSC-like cells. In this study, we further examined if
the structure modification also influences the effect of
DS on CSC-like cells. Figure 3a and b show the effect of
different compounds on cancer cell sphere reformation
ability. The results demonstrate that the inhibiting effect
of DDC on sphere reformation was abolished by the
methylation of the thiol group in S-Me-DDC. In con-
trast, the cytotoxic effect of DS on CSC-like cells was
not affected by replacement of the ethyl with methyl
groups. Furthermore, the effect of different compounds
on the expression of CSC markers was examined. In line
with the inhibiting effect on sphere reformation,
S-Me-DDC/Cu lost its inhibiting effect on ALDH activ-
ity. DDC and DS, in combination with Cu, significantly
inhibit the ALDH activity in sphere cells (Fig. 3c and d).
TMDS also inhibited ALDH activity although it did not
reach statistical significance. Cu-DDC blocks the sphere
reformation and inhibits ALDH activity, to a lesser ex-
tent. We also examined the effect of these compounds
on CD44, another CSC marker. In combination with Cu,
DS, TMDS and DDC significantly inhibited the expres-
sion of CD44. Cu-DDC and DS alone also inhibited
CD44 to a lesser extent (Fig. 3e and f). S-methylated
DDC completely lost the inhibiting effect on CD44 ex-
pression. This data suggests that the CSC targeting effect
of DS also depends on the intact thiol group in DS and
DDC. Modification of ethyl groups has no influence on
the anti-CSC activity of DS.
Functional thiol groups are responsible for extracellular
ROS generation
We previously demonstrated that the chelation of DS
and Cu generated ROS extracellularly [19]. In line with
our previous result, DS and DDC reacted with Cu and
generated ROS in cell free medium. Methylation of the
thiol group (S-Me-DDC) completely blocked ROS gen-
eration. In contrast, replacement of the ethyl groups
with methyl groups (TMDS + Cu) had no affect on ROS
activity. The ROS generation was reversed by addition of
NAC into the reaction (Fig. 4a). Using DS as a model,
we examined the reversing effect of NAC on DS and Cu
induced cell death and apoptosis. Figure 4b to d show
that the DS and Cu induced cell death and apoptosis
were reversed by addition of NAC into the culture
medium. It indicates that the cytotoxicity of DS and
DDC in A549 cells was induced, at least partly, by the
ROS generated from chelating reaction between DS,
DDC and Cu.
The thiuram structure is also essential for the cytotoxicity
of DS
The above experiments confirmed the indispensible role
of the thiol groups in the cytotoxicity of DS. Further-
more, we modified the DDC chemical structure and
examine the influence of thiuram structure on the
anticancer activity of DS. For this purpose, we replaced
the nitrogen in DDC with a nitrogen-containing
five-membered heterocycle (4-Imidazoledithiocarboxylic
acid, IDTA) or a phenol (2-Hydroxy-dithiobenzoic acid,
HDTA). The thiol groups are intact in these two com-
pounds but the thiuram structure is disrupted by re-
placing nitrogen with carbon (Fig. 5a). Because chelation
of copper by thiol groups in DS or DDC generates ROS
and is responsible for the cytotoxic effect, we also tested
a six-membered heterocycle with three thiol groups (2,
4, 6-Trimercaptotriazine), a very strong chelator of diva-
lent metal ions, including Cu [33]. The cytotoxicity of
these compounds was examined by MTT assay in com-
bination with 10 μM of CuCl2. Although these
(See figure on previous page.)
Fig. 4 Copper chelation generated ROS was responsible for cytotoxicity. a ROS activity generated from different compounds (10 μM) in combination
with or without CuCl2 (10 μM). H2O2 (1:100 diluted) and dye only were positive and negative control respectively. b The cytotoxicity of
DS was reversed by NAC. The cells were exposed to DS (1 μM) and CuCl2 (10 μM) with or without NAC (2 mM) for 6 h and released in
drug-free medium. c and d The apoptosis induced by DS was reversed by NAC. The cells were exposed to DS (1 μM) and CuCl2 (10 μM)
with or without NAC (2 mM) for 6 h and subjected Annexin V analysis
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compounds can chelate Cu, no ROS was detected when
mixed with Cu (Fig. 5b). Cytotoxic effect was not de-
tected by MTT assay when these compounds were
co-cultured with Cu (Fig. 5c and Table 1). Addition of
TMT, IDTA and HDTA with Cu into the culture
medium did not induce apoptosis (Fig. 5d and e). These
results indicated that in addition to the thiol group, the
thiuram structure in DS and DDC is also essential for
the cytotoxicity in cancer cells. The nitrogen atom and
its position in the chemical structure of DS and DDC
are critical for the cytotoxicity of DS and DDC to cancer
cells.
Discussion
DS shows very strong anticancer activity in laboratory but
not in clinic. Elucidation of the key anticancer chemical
structure of DS will speed up its translation into clinic as a
cancer treatment [34]. The anticancer activity of DS is
Cu(II) and other transition metal ions dependent. The
thiol group is essential for the chelating reaction between
DDC and Cu. After oral administration, DS is rapidly re-
duced in vivo to DDC by plasma glutathione reductase
[35] and albumin [36]. DDC is catalyzed by cytochrome
p450 in liver to form S-Me-DDC and then further oxi-
dized to Me-DETC and MeSO-DETC [26, 37] which are
the active forms of DS with antialcoholism activity [26]. In
this study, we examined the in vitro cytotoxicity of
S-Me-DDC, the major metabolites of DS in the liver. In
combination with Cu, DS and DDC are highly toxic to
cancer cells and target CSC-like cells. In contrast,
S-methylation completely reverses the cytotoxicity of
DDC and abolishes its anti-CSC activity. This result indi-
cates that the methylation of DS in liver may be respon-
sible for the poor response of cancer patients to orally
administered DS. This may explain the discrepancy of
anticancer-efficacy between clinic and laboratory. In order
to translate DS from an anti-alcoholism application into a
cancer treatment, protection of the thiol group is essential.
To this end, we developed intravenously injectable
nanoparticle-encapsulated DS to protect the thiol group. In
combination with copper, the nano-encapsulated DS has
demonstrated very strong anticancer efficacy in mouse
models [11, 14]. In contrast, substitution of the ethyl groups
with methyl groups did not significantly affect the
cytotoxicity. In combination with Cu, TMDS blocked
sphere-reformation and inhibited CSC traits in lung
cancer cell line. This observation is consistent with
the previous report that the ethyl groups substituents
have no influence on the reaction of metal chelation
[38]. The copper-dependent proteasome-inhibitory and
apoptosis-inducing activity of DS was not affected by
replacing the ethyl groups with pyrrolidine, morpholine
and piperazine [39, 40]. The ethyl groups and their sub-
stitution determine the hydrophilicity of the com-
pounds. TMDS is more hydrophilic than DS and thus it
has less ability to penetrate into cancer cells. This ex-
plains why TMDS is less toxic (Fig. 2b and c). Similar
result were observed when the ethyl groups were
substituted with a pyrrolidine ring attached with a
hydrophilic hydroxyl group [39].
Cu-DDC is also toxic to lung cancer cells and targets
CSC-like cells. Copper, a redox metal ion, can produce
ROS using Fenton and Haber Weiss reactions and in-
duce apoptosis [34]. Development of copper-based drugs
has been very attractive for anticancer drug development
[41, 42] but transport of copper into cells is strictly regu-
lated by a trans-membrane copper transporter Ctr1 [5].
Cu-DDC is highly lipophilic and can bypass the copper
transporter system to penetrate into cells freely [4]. De-
composition of DDC inside cells may release the che-
lated copper, which will generate oxidative stress,
resulting in damage to DNA, RNA and protein. The
Cu-DDC induced intracellular ROS activity has been re-
ported in our previous studies [10, 13]. When the cells
were treated with DS in medium containing CuCl2, the
intracellular copper concentration was rapidly increased
8-fold [4]. Both the intracellular Cu uptake and DS in-
duced toxicity was blocked by co-incubation with batho-
cuproine disulfonic acid, a non-membrane-permeable
Cu chelator. A recent report suggests that Cu-DDC is a
major functional anticancer unit of DS [15]. In compari-
son with DS and DDC, Cu-DDC is more stable in the
bloodstream [43] and easier to develop as a new
copper-based anticancer drug.
We also examined the role of the thiuram structure
(Fig. 1a) on the anticancer activity of DS and DDC. In
Table 1 Cytotoxicity of disulfiram related compounds in A549
cell line
IC50 (μM)
TMT + Cu > 10
HDTA + Cu > 10
IDTA + Cu > 10
(See figure on previous page.)
Fig. 5 Thiuram structure is essential for anticancer activity of DS. a Chemical structures of thiol group containing compounds without thiuram
structure. b Cytotoxicity of TMT, HDTA and IDTA on A549 cells. The cells were exposed to the compounds in combination with CuCl2 (10 μM) for
72 h and subjected to MTT assay. c and d Apoptotic status of A549 cells exposed to 10 μM of TMT, HDTA, IDTA in combination with CuCl2 (10
μM). The cells were treated with the above chemicals for 6 h and then subjected to Annexin V analysis. e Extracellular ROS detection. ROS activity
generated from the mixture of TMT, HDTA, IDTA (10 μM of each) and CuCl2 (10 μM) was measured. H2O2 (1:100) was used as a positive control
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HDTA and IDTA, the nitrogen in DDC is replaced by
hydroxyl benzene and imidazole respectively, while TMT
has intact thiol groups. All of these compounds are very
strong copper chelators. The copper complex generated
by the reaction is highly hydrophobic and can easily
penetrate into cells. There was no extracellular ROS
generated when these compounds were mixed with Cu
(Fig. 5b) and no cytotoxicity or apoptosis was observed
when the cells were cultured at the high concentration
of these compounds (10 μM) and Cu. Our results indi-
cated that along with the thiol groups, the thiuram
structure is also essential for the anticancer activity of
DS and DDC.
Conclusions
The high and selective anticancer activity of DS in the
laboratory has been known for more than three decades
but no promising clinic data were published. We hy-
pothesized that the discrepancy between laboratory and
clinic was introduced by the metabolism of DS in cancer
patients. The anticancer activity is dependent on ROS
generated from the reaction between DS and copper and
the final product, Cu-DDC. When orally administered,
DS is enriched in liver and promptly metabolized to
S-methyl and S-glucuronide DDC. The S-methylation
and glucuronidation block the chelation of DS with cop-
per and compromise its anticancer activity although the
antialcoholism function remained. In this study, we first
demonstrated that the S-methy-DDC, one of the major
metabolites of DS in liver, had no cytotoxicity in cancer
cells. Our study also suggested that the thiuram struc-
ture in the DS is also indispensible for its anticancer ac-
tivity. In contrast, modification of the ethyl groups in DS
did not significantly affect its cytotoxicity in cancer cells.
The findings in this study indicates that a delivery sys-
tem to protect the thiol groups in DS or development of
a soluble Cu-DDC formulation will pave the path for
translation of DS into cancer therapeutics.
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